Remitch OD (nalfurafine hydrochloride orally disintegrating tablet)
/ Toray, Japan Tobacco, Sumitomo Pharma, 3SBio
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
September 04, 2025
KARE-PD: Efficacy and Safety of Nalfurafine Hydrochloride ODT for Moderate-to-Severe Pruritus in Patients on Peritoneal Dialysis
(clinicaltrials.gov)
- P=N/A | N=93 | Recruiting | Sponsor: Guangdong Provincial People's Hospital | Not yet recruiting ➔ Recruiting
Enrollment open • Chronic Kidney Disease • Dermatology • Nephrology • Pruritus • Renal Disease
August 02, 2025
KARE-PD: Efficacy and Safety of Nalfurafine Hydrochloride ODT for Moderate-to-Severe Pruritus in Patients on Peritoneal Dialysis
(clinicaltrials.gov)
- P=N/A | N=93 | Not yet recruiting | Sponsor: Guangdong Provincial People's Hospital
New trial • Chronic Kidney Disease • Dermatology • Nephrology • Pruritus • Renal Disease
September 20, 2024
Clinical Study on the Efficacy and Safety of Nalfurafine Hydrochloride Orally Disintegrating Tablets in the Treatment of Refractory Pruritus in Patients with Non-Dialysis CKD Stages 3-5
(ChiCTR)
- P=N/A | N=95 | Not yet recruiting | Sponsor: Zhongshan Hospital, Fudan University; Zhongshan Hospital, Fudan University
New trial • Chronic Kidney Disease • Dermatology • Nephrology • Pruritus • Renal Disease
January 28, 2021
A Multi-site Bridging Study of Nalfurafine Hydrochloride Orally Disintegrating Tablet
(clinicaltrials.gov)
- P3; N=135; Recruiting; Sponsor: Shenyang Sunshine Pharmaceutical Co., LTD.
Clinical • New P3 trial • Dermatology • Pruritus • Renal Disease
1 to 4
Of
4
Go to page
1